Mirum Pharmaceuticals Inc. (MIRM) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Mirum Pharmaceuticals Inc. (MIRM:NASDAQ), powered by AI.

Current Price
$101.55
P/E Ratio
-218.2
Market Cap
5.1B
Sector
Healthcare
What is the Mirum Pharmaceuticals Inc. stock price forecast?

Mirum Pharmaceuticals Inc. is currently trading at $101.55. View real-time AI analysis on Alpha Lenz.

What is Mirum Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Mirum Pharmaceuticals Inc. on Alpha Lenz.

What is Mirum Pharmaceuticals Inc.'s P/E ratio?

Mirum Pharmaceuticals Inc.'s P/E ratio is -218.2.

Mirum Pharmaceuticals Inc.

NASDAQ · MIRM
$101.55+0.55(+0.54%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Mirum Pharmaceuticals Inc.'s future dividend policy...
Alpha Chat Insight

Mirum Pharmaceuticals Inc. trades at a P/E of -218.2 (undervalued) with modest ROE of -8.6%. 3Y revenue CAGR of 89.1% highlights clear growth momentum.

Ask for details

Company Overview

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases. Its primary objective is to address unmet medical needs, particularly in the sphere of liver diseases where few treatment options exist. Mirum is especially recognized for its work on conditions like Alagille syndrome, a rare genetic disorder affecting the liver, heart, and other parts of the body. The company is committed to advancing its research to offer novel solutions, facilitating regulatory approval processes, and ensuring global access to its therapies. Mirum Pharmaceuticals plays an essential role in the healthcare sector, providing essential treatment options that can significantly improve the quality of life for patients with chronic and challenging illnesses. Its contributions are vital for advancements in the understanding and management of complex liver diseases, making it a key player in the biopharmaceutical landscape, serving the needs of niche patient populations with precision medicine.

CEOMr. Christopher Peetz
SectorHealthcare
IndustryBiotechnology
Employees349

Company Statistics

FY 2025

Profile

$5.10BMarket Cap
$521.31MRevenue
0.00Shares Out
349Employees

Margins

80.77%Gross
3.30%EBITDA
-4.25%Operating
-4.11%Pre-Tax
-4.48%Net

Valuation

-218.19P/E
16.20P/B
9.78EV/Sales
297.59EV/EBITDA
92.90P/FCF

Growth (CAGR)

89.13%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-3.09%ROA
-8.65%ROE
-0.93%ROIC

Financial Health

$296.68MCash & Cash Equivalents
$231.44MNet Debt
167.82%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Mirum Pharmaceuticals Inc. (ticker: MIRM) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 349 employees. Market cap is $5.1B.

The current price is $101.55 with a P/E ratio of -218.19x and P/B of 16.2x.

ROE is -8.65% and operating margin is -4.25%. Annual revenue is $521M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Mirum Pharmaceuticals Inc. (MIRM) Stock Forecast 2026 $101.55 — Price, Financials & Analyst Targets | Alpha Lenz